Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus-Reference-Cited by-同舟云学术

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Published:2011-03-24 Issue:6 Volume:41 Page:524-529
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:

Author:

Arase Yasuji,Suzuki Fumitaka,Kobayashi Mariko,Suzuki Yoshiyuki,Kawamura Yusuke,Matsumoto Naoki,Akuta Norio,Imai Norihisa,Kobayashi Masahiro,Sezaki Hitomi,Saito Satoshi,Hosaka Tetsuya,Ikeda Kenji,Kumada Hiromitsu,Ohmoto Yuki,Amakawa Kazuhisa,Tsuji Hiroshi,Hsieh Shium Dong,Kobayashi Tetsurou

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1872-034X.2011.00798.x/fullpdf

Reference26 articles.

1. Review of hepatitis C in Japan;Kiyosawa;J Gastroenterol Hepatol,1991

2. The natural history of community acquired hepatitis C in the United States;Alter;N Engl J Med,1992

3. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C;van Rossum;Aliment Pharmacol Ther,1998

4. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma;Colombo;Lancet,1989

5. Hepatitis C-associated hepatocellular carcinoma;Hasan;Hepatology,1990

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025;Zeitschrift für Gastroenterologie;2022-09

2. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-06

3. Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS);Clinical Endocrinology;2021-12-21

4. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism;International Journal of Molecular Sciences;2019-09-14

5. Managing diabetes and liver disease association;Arab Journal of Gastroenterology;2018-12